熱門資訊> 正文

Genmat结束晚期肿瘤学资产acasunlimab的开发

2025-12-29 23:07

Genmab A/S(GMAB) 0
Merus(MRUS) 0

Genmab (GMAB) has decided to discontinue development of acasunlimab, which was in phase 3 for non-small cell lung cancer, to focus on other assets in its pipeline as well as its marketed product, Epkinly (epcoritamab), which is approved for lymphomas.
The asset , a bispecific antibody targeting PD-L1 and 4-1BB, was also in phase 2 for advanced melanoma and phase 1 for solid tumors.
The Danish pharma said the decision would not impact its 2025 financial guidance.
Separately, Genmab noted that it has completed its tender offer of outstanding shares of Dutch pharma Merus (MRUS) as part of the latter's $8B acquisition.

More on Genmab

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma
Genmab Q3 2025 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。